Organization (Other)
U.S. Army Medical Research and Development Command
ClinicalTrials.gov lists U.S. Army Medical Research and Development Command as lead sponsor of 153 trials. It has 45 active development programs and 11 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.8 trial starts a year over the five years to September, under the 5 a year the method needs. 2 trials are registered to start in 2027 or later.
Logo Army Medicine, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers U.S. Army Medical Research and Development Command: 153 lead-sponsored trials and 0 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (153)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| Brain Injuries | 40 |
| Malaria | 39 |
| Brain Injuries, Traumatic | 37 |
| Stress Disorders, Post-Traumatic | 26 |
| Dengue | 18 |
Showing 5 of 153 disease areas.
Trials by start year as sponsor or collaborator (29)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 5 |
| 2022 | 7 |
| 2021 | 7 |
| 2020 | 6 |
| 2019 | 6 |
| 2018 | 11 |
| 2017 | 9 |
Showing 10 of 29 years.
Prediction, not a registry value: median of 24 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 114 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (45)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| TREATMENT ARM: Full dose | Combat Disorders | Phase 2 | 1 |
| TREATMENT ARM: Full dose | Stress Disorders, Post-Traumatic | Phase 2 | 1 |
| CONTROL ARM: Active-controlled | Combat Disorders | Phase 2 | 1 |
| CONTROL ARM: Active-controlled | Stress Disorders, Post-Traumatic | Phase 2 | 1 |
| 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1 | Encephalitis | Phase 2 | 1 |
Showing 5 of 45 active programs.
Approved assets (11)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Paromomycin | 2 |
| Ribavirin | 4 |
| Tafenoquine | 3 |
| Sodium Stibogluconate | 3 |
| Mefloquine | 2 |
Showing 5 of 11 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 47% hit target (n=30) | 46% on time (n=24) |
Biomarker capability evidence (336)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CACYBP | Trial sponsor | Named in trial inclusion criteria |
| CACYBP | Trial sponsor | Named in trial inclusion criteria |
| CACYBP | Trial sponsor | Named in trial inclusion criteria |
| CACYBP | Trial sponsor | Named in trial inclusion criteria |
| CACYBP | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 336 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.
Counted at group level under United States Army Medical Command: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.